HERON THERAPEUTICS, INC. /DE/ (HRTX) Form 8-K — Nov 9, 2026
Heron Therapeutics announced Q3 2026 net revenue of $35.3 million, down 7.8% year over year, with a net loss of $5.0 million and $23.4 million in cash at quarter end. The Acute Care franchise grew 22.5% year over year, with ZYNRELEF up 13.8% to $10.6 million and APONVIE up 49.3% to $4.5 million, while Oncology Supportive Care revenue fell 22.2% to $20.1 million. Most significantly, Heron separately announced a definitive asset purchase agreement under which CorMedix will acquire substantially all of Heron's assets, subject to stockholder approval and customary closing conditions.
Key figures
- Eps
- -0.03
- Revenue
- 35250000
- Revenue Yoy
- -7.8%
- Total Assets
- 230448000
- Aponvie q3 yoy
- 49.3%
- Oncology q3 yoy
- -22.2%
- Zynrelef q3 yoy
- 13.8%
- Adjusted ebitda q3
- 3700000
- Aponvie q3 revenue
- 4530000
- Nine month revenue
- 107627000
- Cinvanti q3 revenue
- 19970000
- Oncology q3 revenue
- 20122000
- Stockholders equity
- 4916000
- Zynrelef q3 revenue
- 10598000
- Acute care revenue yoy
- 22.5%
- Q3 2026 acute care revenue
- 15128000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.